Specialty drug access in Morocco: the DMP named-patient pathway

Last reviewed 2026-05-18 by Reserve Meds clinical and regulatory team.

Quick orientation for Morocco

The Kingdom of Morocco operates the DMP autorisation temporaire d'utilisation (ATU) named-patient pathway. The pathway is administered by the Direction du Medicament et de la Pharmacie of the Moroccan Ministry of Health and Social Protection, allows a Moroccan-licensed physician at a registered tertiary facility to import an unregistered or unstocked FDA-labelled medicine for a specific named patient, and runs on 14 to 30 business days routine; 6 to 10 weeks for complex first-import. Cost in MAD trading at approximately 10 MAD to 1 USD, with annual drug cost for an oncology biologic typically in the USD 28,000 to USD 220,000 band at US WAC equivalents.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

Reserved for you.

Why Moroccan patients face an access gap

The Kingdom of Morocco maintains a structured pharmaceutical regulatory environment. The local market registers and stocks an extensive core formulary across cardiology, endocrinology, antibiotics, and oncology, but four converging gaps drive cross-border named-patient demand.

First, indication lag. Specialty oncology, immunology, and rare-disease products approved at the US FDA in the past 24 to 36 months frequently lag local registration. A Moroccan oncologist with an FDA-label-fit case may face a 12 to 36 month delay before the drug arrives through routine commercial channels. Second, presentation gaps. The exact strength, weight-banded pediatric dose, or pen format the prescriber needs may be missing even when the molecule is on the local register. Third, payer denial. The Assurance Maladie Obligatoire (AMO) administered by CNSS and CNOPS, the RAMED scheme for low-income households, and the major private health insurers including Saham Assurance, RMA, AXA Assurance Maroc, and Wafa Assurance employer plans each assess specialty therapies case by case; step-therapy or formulary rules often produce denials even when the drug is locally registered. Fourth, continuity of supply. Moroccan patients stabilised on a US-sourced regimen during US-based care or family visits sometimes need to continue that exact presentation rather than switch to a different local formulation.

In each pattern, the DMP autorisation temporaire d'utilisation (ATU) named-patient pathway is the legal mechanism that connects a Moroccan-licensed physician's clinical decision with US-sourced, FDA-labeled product for a specific patient.

The regulator: the Direction du Medicament et de la Pharmacie of the Moroccan Ministry of Health and Social Protection

The Direction du Medicament et de la Pharmacie of the Moroccan Ministry of Health and Social Protection, commonly abbreviated as DMP, is the Morocco national authority responsible for the registration, licensing, and surveillance of human medicinal products. The agency operates alongside the the Conseil National de l'Ordre des Medecins and the DMP; the combination of professional licensing (physician and pharmacy) with product licensing (medicine and manufacturer) defines the legal envelope within which the DMP autorisation temporaire d'utilisation (ATU) named-patient pathway operates.

The agency publishes its current regulatory guidance on its public portal. Reserve Meds maintains a reading list of the current circulars and acts that govern personal-import authorisation; the regulator's guidance is the controlling source. Reserve Meds' role is to translate the documentation expectations into an applicant-ready packet, not to act as the regulator.

The named-patient route exists precisely because no regulator can register every FDA-approved indication, presentation, and dose-band the moment the FDA approves it. The mechanism is a principled exception, not a workaround. Reserve Meds operates exclusively within the principled-exception envelope.

The DMP named-patient pathway in detail

The pathway for a Moroccan-licensed physician to obtain a medicine that is not registered or not stocked locally is the autorisation temporaire d'utilisation (ATU) named-patient pathway administered by the Direction du Medicament et de la Pharmacie (DMP) under Law No. 17-04 (Code du Medicament et de la Pharmacie) and its implementing decrees, which allows a treating physician at a registered tertiary facility to apply to the DMP for the import of an unregistered medicine for a specific named patient where the medicine is approved by a recognised reference authority (typically the US FDA, EMA, or French ANSM) and no clinically equivalent locally registered alternative is suitable. The framework allows registered healthcare facilities to import a specific medicine for a specific patient when the medicine is approved by a recognised reference authority (US FDA, EMA, MHRA, PMDA Japan, or Health Canada) and a clinically equivalent locally registered alternative is not suitable.

A complete application typically includes: (1) a clinical justification letter from the treating physician naming the diagnosis, severity, prior therapies, why this specific drug, and why the locally stocked option is not suitable; (2) the treating physician's Moroccan medical license verification via the Conseil National de l'Ordre des Medecins and the DMP; (3) an anonymised patient identifier where DMP submission rules allow; (4) full product details including brand name, generic name, manufacturer, strength, dosage form, pack size, requested quantity, and intended treatment duration; (5) the destination dispensing facility name, license number, and pharmacy in charge; (6) a chain-of-custody plan from US manufacturer through importer to dispensing pharmacy.

Approval timelines for routine cases run 14 to 30 business days from a complete filing. Complex first-import cases (rare indication, larger quantities, first pediatric or weight-banded format) extend to 6 to 10 weeks. DMP retains discretion on timing and we never promise specific durations.

The Morocco payer landscape

Morocco health financing combines public coverage and private insurance in proportions that vary by socioeconomic stratum and by treatment setting. The major payers we see in named-patient imports are the Assurance Maladie Obligatoire (AMO) administered by CNSS and CNOPS, the RAMED scheme for low-income households, and the major private health insurers including Saham Assurance, RMA, AXA Assurance Maroc, and Wafa Assurance employer plans.

Public coverage typically reimburses essential-medicine list items at the dispensing pharmacy with co-payment, but specialty oncology biologics and gene therapies frequently fall outside the public formulary. Private insurance plans assess named-patient imports against individual policy terms; pre-authorisation is the rule, not the exception, and the documentation set Reserve Meds prepares is designed to support the pre-authorisation submission to the insurer as well as the DMP application itself.

For cash-pay families (the majority of cross-border specialty cases globally), Morocco pricing is informed by US WAC equivalents plus international logistics. The annual cost band for an oncology biologic at FDA-labelled adult dosing typically falls in the USD 28,000 to USD 220,000 range at US WAC equivalents in the Morocco market, with the dispensing hospital adding its infusion or administration fee separately. Reserve Meds itemises the concierge fee on every firm quote; we do not bundle drug cost into a single line.

Top hospitals handling named-patient imports in Morocco

A small group of tertiary and major private hospitals in Morocco handle named-patient imports as established workflow. These centres maintain in-house import-pharmacy infrastructure, physicians experienced with the DMP application set, and validated cold-chain storage (2 to 8 degrees Celsius for biologics, ultra-cold or specialised handling where the FDA label requires it). The most active centres are Centre Hospitalier Universitaire Ibn Rochd in Casablanca, Sheikh Khalifa Hospital in Casablanca, Centre Hospitalier Universitaire Ibn Sina in Rabat, the Institut National d'Oncologie (INO) in Rabat, and Clinique Internationale Cheikh Zaid in Rabat.

For physicians at smaller hospitals without internal import infrastructure, the standard pattern is to route through a specialty importer that holds a pharmaceutical establishment license and files the DMP application on the prescribing physician's behalf. The medicine then moves into the prescribing hospital's outpatient or specialty pharmacy under chain-of-custody documentation that Reserve Meds prepares and the importer co-signs.

Common indications driving named-patient demand in Morocco

Across cases we coordinate or anticipate coordinating in the Morocco market, four therapeutic areas dominate named-patient demand. Oncology accounts for the majority of cross-border specialty cases: PD-1 and PD-L1 checkpoint inhibitors (Keytruda, Opdivo, Tevimbra), antibody-drug conjugates (Tivdak, Datroway), tyrosine kinase inhibitors (Lazcluze, Ibtrozi, Ensacove), bispecific T-cell engagers (Talvey, Tecvayli, Tepkinly, Imdelltra), and PARP inhibitors (Zejula). Rare-disease gene therapies form a fast-growing second tier: hemophilia gene therapy (Roctavian, Hemgenix), sickle cell disease (Lyfgenia), metachromatic leukodystrophy (Lenmeldy), and recessive dystrophic epidermolysis bullosa (Zevaskyn).

The third group is immunology and dermatology biologics where Morocco local label or stocking lags the US FDA approval window: newer IL-13 and IL-17 inhibitors and JAK inhibitors at expanded indications. The fourth group is pulmonary hypertension, cardiology, and metabolic-disease specialty products where small-molecule and biologic options have crossed FDA approval but not local registration: Winrevair, Wainua, Qfitlia, Alhemo, Vyondys 53. Reserve Meds maintains a per-drug, per-country matrix detailing the named-patient pathway for each of these molecules in Morocco.

Quality, chain-of-custody, and DSCSA compliance for Morocco cases

Every medicine Reserve Meds coordinates is sourced from the US manufacturer through a Drug Supply Chain Security Act (DSCSA)-compliant specialty channel. The DSCSA mandates serialised tracing of every saleable unit from manufacturer through wholesale distributor to dispensing pharmacy in the United States. For cross-border named-patient supply to Morocco, we maintain the DSCSA chain to the point of US export and preserve the documented lineage in the chain-of-custody record that accompanies the international shipment. This is the operational answer to the counterfeit concern that haunts the global specialty market: the Morocco patient receives a unit whose lineage can be traced back to the US manufacturer with full serialisation data.

Cold-chain integrity is the second pillar. Most specialty biologics (monoclonal antibodies, antibody-drug conjugates, fusion proteins, gene therapies) require continuous 2 to 8 degrees Celsius storage from manufacturer through dispensing pharmacy. Our cold-chain protocol uses qualified passive or active containers, continuous temperature data loggers, and validated lane planning with stability data overlaid on the expected transit time. Ultra-cold (-20 degrees or below) products require dry-ice or phase-change-material containers with explicit lane qualification. The dispensing pharmacy in Morocco confirms storage compliance on receipt; the cold chain is broken only at the dispensing pharmacy under documented control. Excursion handling follows the manufacturer's labelled stability runway: a documented out-of-range excursion triggers an immediate medical-affairs review and, where required, product replacement.

Cost and currency picture in Morocco

MAD is trading at approximately 10 MAD to 1 USD. For a typical oncology biologic at FDA-labelled adult dosing, the US WAC-equivalent annual cost in the Morocco market falls between USD 28,000 and USD 220,000. International logistics adds USD 400 to USD 1300 per shipment depending on destination city, urgency, and cold-chain requirements. DMP permit fees are nominal relative to drug cost.

Reserve Meds builds the firm quote against current US manufacturer list pricing (Pfizer, Merck, Roche, BMS, Lilly, Novartis, AstraZeneca, AbbVie, Regeneron, and others as applicable to the prescribed drug) and itemises each line: drug cost, international logistics, DMP permit and customs fees, and the Reserve Meds concierge fee. Manufacturer copay cards and patient-assistance programmes available to US patients do not extend internationally; cross-border patients pay cash or rely on local payer coverage.

We do not act as a price negotiator with the US manufacturer. We do act as a transparent line-item intermediary: every quote shows the manufacturer-pass-through drug cost as a separate line so the patient and physician can see exactly what they are paying for. That transparency is central to the trust posture we maintain with Morocco families and prescribers.

Typical end-to-end timeline in Morocco

DMP routine processing is typically 14 to 30 business days from a complete filing. International logistics adds 2 to 5 additional days depending on whether the presentation is ambient or cold-chain, the dispensing city, and customs clearance. End-to-end, most routine adult cases complete within 3 to 6 weeks from first complete documentation. Complex first-import cases run to 6 to 10 weeks.

The binding step is rarely the DMP review itself when the application is filed clean. It is usually documentation completeness on the prescriber's side or, for cold-chain biologics, the dispensing facility's storage and monitoring confirmation. The intake is where Reserve Meds locks the case-team contact, gathers documents in parallel, and starts the US sourcing clock so that approval and product land in the same week rather than serially.

What your physician needs to provide

For a Moroccan-licensed specialist filing through DMP, the clinical justification letter is the cornerstone of the application. The letter documents the patient's confirmed diagnosis, severity assessment (scoring instrument, biomarker, imaging, or biopsy as appropriate), prior therapy history including first-line options tried, and a clinical rationale for the prescribed medicine given its FDA-labelled mechanism.

The letter specifies the exact dosing plan per the FDA-approved label: starting dose, maintenance dose, route of administration, schedule, and intended duration of therapy. Monitoring plan references any baseline laboratory or imaging requirements specific to the medicine, planned follow-up intervals, and dose-modification criteria for the most common adverse events.

The treating physician's Moroccan license number (verifiable via the Conseil National de l'Ordre des Medecins and the DMP), the dispensing facility license number, and the pharmacy in charge of dispensing complete the package. For cold-chain or specialty-handling products, the dispensing pharmacy's documented storage protocol and continuous-temperature-monitoring log are part of the chain-of-custody record Reserve Meds shares with the importer.

Morocco specialty-drug access: where the Casablanca-Rabat axis works and where it does not

Morocco's Direction du Médicament et de la Pharmacie (DMP) under the Ministry of Health operates the autorisation temporaire d'utilisation (ATU) framework for unregistered specialty drugs. Most cross-border cases concentrate in two hubs: Casablanca (CHU Ibn Rochd, Cheikh Khalifa, multiple private oncology centers) and Rabat (CHU Ibn Sina, Hôpital militaire Mohammed V). The Marrakech and Fès tertiary centers handle regional cases but typically refer specialty-import logistics back to Casablanca-based specialists for the documentation pathway.

Morocco's NPP review timing varies more widely than GCC countries, 4 to 12 weeks depending on the specific therapy class and the prescribing physician's prior history with DMP. French-language documentation is preferred but English is accepted with translation; we routinely supply French translation of the clinical package, as this reduces back-and-forth with the reviewer.

CNOPS and CNSS coverage rarely extends to NPP-sourced unregistered drugs. Private insurance (Saham, RMA, Wafa) varies plan-to-plan with most defaulting to denial on first pass. Self-pay is the most common funding rail; escalation appeals with full clinical documentation occasionally succeed at the platinum-tier level. The Casablanca specialty pharmacy network is well-developed for downstream patient support, and we coordinate with the patient's chosen pharmacy for administration support where the therapy requires it.

Cold-chain shipping into Casablanca works through direct flights from Frankfurt or Paris with 48 to 72 hours customs clearance once ATU paperwork is appended. We handle the documentation and routing; the family deals only with the pharmacy handoff at the destination.

More questions, specific to this case

Is DMP approval valid across all Moroccan hospitals or just the requesting one?

Approval is patient-specific and physician-specific. A second physician at a different hospital would need a separate ATU for the same patient.

How does cold-chain shipping into Casablanca work?

Direct flights from Frankfurt or Paris into Casablanca enable validated cold-chain shipments with 48 to 72 hours customs clearance once ATU paperwork is appended.

Are gene therapies accessible via Morocco NPP?

Technically yes via ATU. Practically, the funding gap is the binding constraint, we walk through the all-in figure with the family before any submission.

Where Reserve Meds fits in Morocco cases

Reserve Meds is a US-based concierge coordinator. We do not replace your treating physician, we do not replace DMP, and we do not replace your dispensing pharmacy. For Morocco cases specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it) into Morocco, and assign a single named coordinator through the case.

Operationally, a typical Morocco case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing plan, monitoring schedule. The regulatory track is the DMP application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment. The patient-experience track is the named coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks are run in parallel rather than in series; that is the operational difference between a 3-week and a 9-week case.

Reserve Meds is not an insurer, not a benefits administrator, and not a substitute for legal advice in Morocco. Regulatory posture on this page is informational; case-specific questions route to retained outside counsel.

Next step for Morocco patients

If your Moroccan physician has prescribed a US-sourced specialty medicine through the DMP autorisation temporaire d'utilisation (ATU) named-patient pathway, the next step is a short intake request. Reserve Meds confirms eligibility within 24 to 48 hours and sends a documentation kit to your physician. The kit includes the clinical justification letter template, the DMP application checklist, the chain-of-custody attestation form, and the cold-chain monitoring receipt log. Your physician fills the clinical sections; we file the regulatory sections with the importer. Patient and physician track the case in real time through the Reserve Meds patient portal.

Start your caseWhatsApp

Reserved for you.